A Phase 4 interventional study of Elagolix Oral Tablet and Estradiol patch in Menopause and Aging, sponsored by Penn State University. Recruiting at 1 site in United States. Open to female participants aged 42 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Penn State University · Phase 4, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Heat Stress Disorders with a site in United States — 11 open to participants now, 13 under way, none of them phase 3. Heat Stress Disorders · United States.
Among the 33 studies in Heat Stress Disorders with a site in United States, this one is the 14th largest by planned enrollment of the 27 interventional ones that give a count, is one of 9 that started in 2025, is one of 2 in phase 4, reaches primary completion later than 5 of the 12 other live ones, and was the 20th registered.
118 studies on the registry are indexed under Heat Stress Disorders; 42 are open to participants now.
Browse Heat Stress Disorders studies →11 of the 33 studies in Heat Stress Disorders with a site in United States are open now. Recruiting first, the newest first:
Hartford Hospital · Sites in United States
Ages 18–25
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–60
University of Northern Iowa · Sites in United States
Ages 18–45 · Healthy volunteers
Providence College · Sites in United States
Ages 18–45 · Women only · Healthy volunteers
Harvard School of Public Health (HSPH) · Sites in United States
Ages 55–95
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 30 Heat Stress Disorders studies recruiting now, 8 (27%) set no upper age limit and 18 (60%) stop at 75 or younger; 6 take children under 18; 22 take healthy volunteers.
This study: 42 Years to 64 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is close to the median of 24 across 104 interventional studies indexed under Heat Stress Disorders.
Median enrollment 24 across the 27 interventional studies, 27 across the 6 observational. Of the 19 that completed or were terminated, 2 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 33 has an industry lead sponsor. The 10 most frequent:
Penn State University is the lead sponsor of 271 studies on the registry; 54 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 11 (73%) have results posted.
Penn State University has 4 studies filed under Heat Stress Disorders — fewer than ten, so there is no comparison to draw.
6 of the studies in Heat Stress Disorders with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03042988Vanderbilt University Medical CenterOvernight Trials With Heat Stress in Autonomic Failure Patients With Supine Hypertension | 2026-11-30 |
| NCT06798571Penn State UniversityRole of Menopause in Thermoregulation | 2026-12-01 |
| NCT04284397Penn State UniversityIdentification of Critical Thermal Environments for Aged Adults | 2027-02-27 |
| NCT07472426University of Northern IowaEffects of Creatine Supplementation on Cognitive Measures and Markers of Acute Kidney Injury After Exercise in the Heat | 2027-03 |
| NCT06475339State University of New York at BuffaloPredicting Responses to Exhausting, Prolonged, And Repeated Exercise Demands (PREPARED) for Heat | 2027-03 |
Add all 6 to your calendar (.ics) → With an account.
Among the 33 studies in Heat Stress Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The frequency and severity of heat waves has increased in the last decades. Older adults (over 65 years) have impaired responses to heat stress making them at increased risk for adverse events. Previous heat waves report that women over 65 experience worse health outcomes than any other age group and age matched men.
Aging and reproductive hormones, specifically estrogen, independently alter responses to heat stress. However, the combined effects of low estrogen following menopause and aging on the response to heat stress are unknown. In this study, the investigators will identify the role of estrogen in pre and post menopausal women on thermoregulatory responses to heat stress.
Premenopausal and postmenopausal women will be recruited and different interventions will be given to each group. To mimic a postmenopausal hormone profile, premenopausal women will be given a GnRH antagonist, which acutely reduces estrogen concentrations. This induces a temporary post-menopausal state without compounding aging effects. Postmenopausal women will be given a transdermal estradiol patch to acutely raise estrogen concentrations. Supplementing estrogen in postmenopausal women allows for the effect of menopausal low estrogen concentration to be removed from the physiological effects of aging.
Subjects sign an informed consent form and undergo a medical screening prior to participation. The screening includes a physical exam, anthropometry, chemical and lipid profiles.
Each subject will complete 6 (3 for each treatment) experimental trials. For each intervention, participants will complete one passive heating experiment first, followed by two active heating experiments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants take a cellulose placebo tablet for 4 days prior to baseline testing and continue until experimental visits are complete. Following completion of placebo testing, participants begin taking 400 mg/day Elagolix for 4 days prior to testing and continue until experimental visits are complete.
Drug: Elagolix Oral Tablet · Other: cellulose placebo
Participants wear a transdermal estradiol patch or placebo patch for 5 days prior to testing and continue until experimental visits are complete. After 48 hr washout, participants then wear the alternative treatment for 5 days prior to testing until experimental visits are complete.
Drug: Estradiol patch · Other: placebo patch
2 x 200 mg tablet
Also known as: Orilissa
0.05 mg/day patch
placebo tablet
placebo patch
Skin Blood Flow
Skin blood flow response to whole body heating is continuously monitored
Time frame: Monitored continuously during both 3 hour passive heating experiments (Visit 1 and Visit 3 approx 3 weeks)
Local Sweat Rate
A small sweat capsule is placed on the forearm for the duration of whole body heating.
Time frame: Monitored continuously during both 3 hour passive heating experiments (Visit 1 and Visit 3 approx 3 weeks)
Core Temperature
Changes in body temperature are measured through a telemetry pill swallowed before each experiment.
Time frame: Monitored continuously during all 3 hour experimental visits (6 total average of 3 weeks)
Body Mass
Body mass is measured on a scale.
Time frame: Baseline and following 3 hr experimental visit (6 total visits for study completion, an average of 3 weeks)
Skin Temperature
Mean skin temperature is calculated from a weighted average of skin temperature from 4 different sites.
Time frame: Calculated continuously for the duration of each 3 hr experimental visit (6 total visits for study completion, an average of 3 weeks)
Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Sep 2026 → Dec 2026 and completion Sep 2026 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elagolix · Estradiol